Public Market Listing
ROVIBME
Live quotes, historical charts, and market capitalization for Laboratorios Farmacéuticos Rovi, S.A. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
3 September 2025WithdrawalRisperidone (Risvan)FDA withdraws approval of NDA 214835 (Federal Register 2025-14683)
US, FDA · Source ↗
Financial reports
No financial reports recorded.